Developer docs
API playgroundTry for free, no card

Search company profiles

Consonance Capital Partners

Full company profile

uuid0000sft

Namestring
Consonance Capital Partners
Legal namestring
Consonance Capital
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Consonance Capital is a healthcare-focused investment platform established in 2005 and headquartered at 545 Madison Avenue, 7th Floor, New York. The platform operates through two entities: Consonance Capital Partners, a private equity manager executing growth equity investments, leveraged buyouts, and recapitalizations in U.S. healthcare companies; and Consonance Capital Management, a hedge fund that previously invested in public life sciences but is no longer accepting new investor capital and now oversees only residual administrative matters. The firm is led by founder and CEO Mitchell Blutt, MD, alongside co-founders Benjamin Edmands, Stephen McKenna, and Nancy-Ann DeParle on the PE side, with Kevin Livingston and Benny Soffer, MD as co-founders of the wound-down hedge fund arm.

The firm's operational footprint is a lean team of 11-50 employees based at its single New York headquarters. Its investment product surface is its sector thesis — originating, executing, and managing equity investments across U.S. healthcare sub-sectors. The disclosed acquisition track record spans healthcare services (Psychiatric Medical Care, Kepro, Orsini Healthcare), diagnostics (Bako Diagnostics), and pharma services (Enclara Pharmacia), demonstrating breadth within the healthcare vertical. The technology stack is conventional PE infrastructure; no proprietary technology platform or AI components are described in the available data.

Consonance Capital generates revenue through traditional private equity economics: management fees on committed capital and carried interest on fund returns. Its customer base consists of limited partners committing to its healthcare-focused funds and the healthcare founders and management teams receiving capital and operational support. The firm does not publicly disclose pricing, AUM, fund vintages, or revenue figures. Its narrow vertical focus — exclusively U.S. healthcare — combined with a leadership team drawn from top healthcare investment firms (GTCR, Carlyle, J.P. Morgan) constitutes its principal differentiation, though the firm operates at a smaller scale than mega-fund healthcare peers.

Short descriptiontext

Consonance Capital is a New York-based healthcare investment platform founded in 2005 that operates a private equity arm executing growth equity, leveraged buyouts, and recapitalizations in U.S. healthcare companies, generating revenue from fund management fees and carried interest.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare private equity, growth equity investments, leveraged buyouts, healthcare recapitalizations, healthcare investment platform
Industry3 codes
1Corporate Finance & Capital Advisory
CodeBPAHADABPrimaryYes
2Capital Raising Advisory (Debt/Equity/Private Capital)
CodeBPAHADAGPrimaryNo
3Capital Raising Advisory (Equity & Equity-Linked)
CodeFSAEAGACPrimaryNo
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Investment Banking and Securities Intermediation523150
SIC code2 codes
  • Security Brokers, Dealers & Flotation Companies6211
  • Investment Advice6282
Product category
Healthcare Private Equity
No data
Revenue model1 record
1Private Equity Management
TypeSubscription Recurring
Description

Consonance Capital Partners generates revenue through private equity fund management, including management fees and carried interest from investments in healthcare growth equity, leveraged buyouts, and recapitalizations.

consonancecapital.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Consonance Capital Partners is a private equity manager that invests across the U.S. healthcare industry through growth equity, leveraged buyouts, and recapitalizations. The platform also operates Consonance Capital Management, a hedge fund that historically invested in public life sciences, though that arm is no longer making new equity investments or accepting investor capital. Founded in 2005, the firm is headquartered in New York and co-leads transactions alongside healthcare founders and management teams.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Consonance Capital operates as a unified healthcare investment platform with two distinct product lines: Consonance Capital Partners (private equity) handles growth equity, leveraged buyouts, and recapitalizations in the U.S. healthcare sector, while Consonance Capital Management (hedge fund) previously managed public life sciences investments. The platform was created in 2005 and is led by CEO Mitchell Blutt, MD, with offices at 545 Madison Avenue, 7th Floor, New York, NY 10022.

Product and service1 record
1Consonance Capital Partners (Private Equity)
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Chicago-based growth-oriented PE firm with a longstanding Healthcare group. Notable because Consonance's new VP Charlie Kolisek previously worked at GTCR's Healthcare group, and the firm is a direct comparable in healthcare buyout activity.

TypeDirect peer
Description

U.S. private equity firm with a dedicated healthcare franchise investing in healthcare services, pharma services, and information. Comparable in healthcare thematic focus and growth-oriented buyout strategy.

TypeDirect peer
Description

Healthcare-dedicated investment firm across PE, growth equity, and royalties, with a focus on biopharma, medical devices, and healthcare services. Comparable healthcare-only thesis and platform-building orientation.

TypeDirect peer
Description

Healthcare-dedicated middle-market PE firm investing in healthcare services, pharma services, and medical products. Direct comparable in vertical focus and platform-building approach to Consonance Capital Partners.

TypeEmerging player
Description

Healthcare-focused growth equity firm investing in lower-middle-market healthcare services and information technology companies. Smaller and earlier-stage than Consonance but comparable in vertical specialization.

TypeBroad incumbent
Description

Global alternative asset manager with a healthcare growth and buyout franchise. Comparable in healthcare deal activity but part of a much larger diversified PE platform.

TypeBroad incumbent
Description

Large diversified alternative asset manager with a dedicated healthcare practice investing across services, biopharma, and digital health. Overlapping in healthcare PE activity but operating as part of a broader multi-strategy platform.

TypeDirect peer
Description

One of the longest-tenured U.S. healthcare-focused PE firms, investing across healthcare services, information, and life sciences. Highly comparable sector specialization, though typically larger fund vintages than Consonance.

TypeDirect peer
Description

Healthcare-focused middle-market private equity firm sponsoring growth equity and buyouts in U.S. healthcare services, pharma services, and medical products — closely comparable to Consonance Capital Partners in sector, stage, and ticket size.

TypeBroad incumbent
Description

Diversified alternative asset manager with a dedicated healthcare vertical spanning services, life sciences, and pharma. Overlaps with Consonance on healthcare buyout deals but at larger scale and broader strategy mix.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment10 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Consonance Capital Partners

Healthcare Private Equityconsonancecapital.com

Consonance Capital is a New York-based healthcare investment platform founded in 2005 that operates a private equity arm executing growth equity, leveraged buyouts, and recapitalizations in U.S. healthcare companies, generating revenue from fund management fees and carried interest.

What Consonance Capital Partners does

Consonance Capital is a healthcare-focused investment platform established in 2005 and headquartered at 545 Madison Avenue, 7th Floor, New York. The platform operates through two entities: Consonance Capital Partners, a private equity manager executing growth equity investments, leveraged buyouts, and recapitalizations in U.S. healthcare companies; and Consonance Capital Management, a hedge fund that previously invested in public life sciences but is no longer accepting new investor capital and now oversees only residual administrative matters. The firm is led by founder and CEO Mitchell Blutt, MD, alongside co-founders Benjamin Edmands, Stephen McKenna, and Nancy-Ann DeParle on the PE side, with Kevin Livingston and Benny Soffer, MD as co-founders of the wound-down hedge fund arm.

The firm's operational footprint is a lean team of 11-50 employees based at its single New York headquarters. Its investment product surface is its sector thesis — originating, executing, and managing equity investments across U.S. healthcare sub-sectors. The disclosed acquisition track record spans healthcare services (Psychiatric Medical Care, Kepro, Orsini Healthcare), diagnostics (Bako Diagnostics), and pharma services (Enclara Pharmacia), demonstrating breadth within the healthcare vertical. The technology stack is conventional PE infrastructure; no proprietary technology platform or AI components are described in the available data.

Consonance Capital generates revenue through traditional private equity economics: management fees on committed capital and carried interest on fund returns. Its customer base consists of limited partners committing to its healthcare-focused funds and the healthcare founders and management teams receiving capital and operational support. The firm does not publicly disclose pricing, AUM, fund vintages, or revenue figures. Its narrow vertical focus — exclusively U.S. healthcare — combined with a leadership team drawn from top healthcare investment firms (GTCR, Carlyle, J.P. Morgan) constitutes its principal differentiation, though the firm operates at a smaller scale than mega-fund healthcare peers.

Consonance Capital Partners firmographics

Firmographics
Name
Consonance Capital Partners
Legal name
Consonance Capital
Website
https://consonancecapital.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
Consonance Capital is a New York-based healthcare investment platform founded in 2005 that operates a private equity arm executing growth equity, leveraged buyouts, and recapitalizations in U.S. healthcare companies, generating revenue from fund management fees and carried interest.
Ownership category
akta.pro rank

Consonance Capital Partners industry classification

Industry
Product category
Healthcare Private Equity
NAICS
Portfolio Management and Investment Advice (523940), Investment Banking and Securities Intermediation (523150)
SIC
Security Brokers, Dealers & Flotation Companies (6211), Investment Advice (6282)
akta.pro primary industry
Corporate Finance & Capital Advisory (BPAHADAB)
akta.pro secondary industries
Capital Raising Advisory (Debt/Equity/Private Capital) (BPAHADAG), Capital Raising Advisory (Equity & Equity-Linked) (FSAEAGAC)

Keywords

  • Healthcare private equity
  • Growth equity investments
  • Leveraged buyouts
  • Healthcare recapitalizations
  • Healthcare investment platform

Where Consonance Capital Partners is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Consonance Capital Partners business model

Business model
GTM type
B2B
Offering type
Services

Revenue model

  1. Private Equity Management: Consonance Capital Partners generates revenue through private equity fund management, including management fees and carried interest from investments in healthcare growth equity, leveraged buyouts, and recapitalizations.

Consonance Capital Partners product offering

Product offering

Core offering

Consonance Capital Partners is a private equity manager that invests across the U.S. healthcare industry through growth equity, leveraged buyouts, and recapitalizations. The platform also operates Consonance Capital Management, a hedge fund that historically invested in public life sciences, though that arm is no longer making new equity investments or accepting investor capital. Founded in 2005, the firm is headquartered in New York and co-leads transactions alongside healthcare founders and management teams.

Product overview

Consonance Capital operates as a unified healthcare investment platform with two distinct product lines: Consonance Capital Partners (private equity) handles growth equity, leveraged buyouts, and recapitalizations in the U.S. healthcare sector, while Consonance Capital Management (hedge fund) previously managed public life sciences investments. The platform was created in 2005 and is led by CEO Mitchell Blutt, MD, with offices at 545 Madison Avenue, 7th Floor, New York, NY 10022.

Differentiator

Problem solved

Functional benefit

Products and services

  • Consonance Capital Partners (Private Equity)

Companies that use Consonance Capital Partners

Customer profile

Segments1 record

Consonance Capital Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Consonance Capital Partners partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights3 records

Consonance Capital Partners competitors and assessment

Company assessment

Direct peers

  • GTCR: Chicago-based growth-oriented PE firm with a longstanding Healthcare group. Notable because Consonance's new VP Charlie Kolisek previously worked at GTCR's Healthcare group, and the firm is a direct comparable in healthcare buyout activity.
  • New Mountain Capital: U.S. private equity firm with a dedicated healthcare franchise investing in healthcare services, pharma services, and information. Comparable in healthcare thematic focus and growth-oriented buyout strategy.
  • OrbiMed Advisors: Healthcare-dedicated investment firm across PE, growth equity, and royalties, with a focus on biopharma, medical devices, and healthcare services. Comparable healthcare-only thesis and platform-building orientation.
  • Linden Capital Partners: Healthcare-dedicated middle-market PE firm investing in healthcare services, pharma services, and medical products. Direct comparable in vertical focus and platform-building approach to Consonance Capital Partners.
  • Welsh, Carson, Anderson & Stowe: One of the longest-tenured U.S. healthcare-focused PE firms, investing across healthcare services, information, and life sciences. Highly comparable sector specialization, though typically larger fund vintages than Consonance.
  • Avista Capital Partners: Healthcare-focused middle-market private equity firm sponsoring growth equity and buyouts in U.S. healthcare services, pharma services, and medical products — closely comparable to Consonance Capital Partners in sector, stage, and ticket size.

Emerging players

  • Health Enterprise Partners: Healthcare-focused growth equity firm investing in lower-middle-market healthcare services and information technology companies. Smaller and earlier-stage than Consonance but comparable in vertical specialization.

Broad incumbents

  • KKR — Healthcare Strategic Growth: Global alternative asset manager with a healthcare growth and buyout franchise. Comparable in healthcare deal activity but part of a much larger diversified PE platform.
  • TPG Capital — Healthcare Team: Large diversified alternative asset manager with a dedicated healthcare practice investing across services, biopharma, and digital health. Overlapping in healthcare PE activity but operating as part of a broader multi-strategy platform.
  • Bain Capital — Healthcare: Diversified alternative asset manager with a dedicated healthcare vertical spanning services, life sciences, and pharma. Overlaps with Consonance on healthcare buyout deals but at larger scale and broader strategy mix.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

Consonance Capital Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Consonance Capital Partners leadership team

Management profile

Number of profiles

Consonance Capital Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Consonance Capital Partners M&A and investment

M&A and investment

M&A5 records

Investments10 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Consonance Capital Partners

What does Consonance Capital Partners do?

Consonance Capital Partners is a private equity manager that invests across the U.S. healthcare industry through growth equity, leveraged buyouts, and recapitalizations. The platform also operates Consonance Capital Management, a hedge fund that historically invested in public life sciences, though that arm is no longer making new equity investments or accepting investor capital. Founded in 2005, the firm is headquartered in New York and co-leads transactions alongside healthcare founders and management teams.

Is Consonance Capital Partners a public or private company?

Consonance Capital Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Consonance Capital Partners founded?

Consonance Capital Partners was founded in 2005. It employs 11 to 50 people.

Where is Consonance Capital Partners based?

Consonance Capital Partners is headquartered in New York, United States, in the North America region.

How does Consonance Capital Partners make money?

One revenue line is on record: private Equity Management.

Who are Consonance Capital Partners's main competitors?

Direct peers on record are GTCR, New Mountain Capital, OrbiMed Advisors, Linden Capital Partners, Welsh, Carson, Anderson & Stowe and Avista Capital Partners. Health Enterprise Partners is listed as an emerging player. Broad incumbents are KKR — Healthcare Strategic Growth, TPG Capital — Healthcare Team and Bain Capital — Healthcare.

Does Consonance Capital Partners have an API?

No public API is recorded for Consonance Capital Partners.

What industry is Consonance Capital Partners in?

Consonance Capital Partners's product category is Healthcare Private Equity. Its primary akta.pro industry code is BPAHADAB, Corporate Finance & Capital Advisory, with a secondary code of BPAHADAG, Capital Raising Advisory (Debt/Equity/Private Capital). Its NAICS code is 523940 and its SIC code is 6211.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogConsonance Capital Partners Closes Oversubscribed Third Fund at $1.35 BillionConsonance Capital Partners closed its third private equity fund, Consonance Private Equity III, at a $1.35 billion hard cap in under four months. The fund is oversubscribed and will invest in U.S. healthcare companies in the lower and middle market.FinancialContent Business PageConsonance Capital Partners Closes Oversubscribed Third Fund at $1.35 BillionConsonance Capital Partners closed its third private equity fund, Consonance Private Equity III, at a $1.35 billion hard cap in under four months. The fund, focused on U.S. healthcare lower and middle market companies, was oversubscribed with support from existing and new investors.Business Wire BlogConsonance Capital Partners Announces Charlie Kolisek as Vice PresidentConsonance Capital Partners, a New York-based private equity firm focused on the U.S. healthcare industry, announced the appointment of Charlie Kolisek as Vice President. Kolisek brings over a decade of healthcare private equity experience, having previously served as an investment professional at GTCR's Healthcare group, and earlier at Carlyle and J.P. Morgan. The firm stated that Kolisek's sector expertise and professional network will support its continued partnership with founders and management teams in building healthcare businesses.Business Wire BlogSurrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue RegenerationSurrozen, Inc. completed its business combination with Consonance-HFW Acquisition Corp., a SPAC sponsored by Consonance Capital Management, to become a publicly traded company on Nasdaq under the ticker SRZN. The transaction was approved by shareholders of both entities in August 2021 and will allow Surrozen to raise capital for the development of its Wnt pathway therapeutics. This merger marks the debut of Surrozen as a public leader in tissue regeneration research.